Last autumn, I was searching for a way to get rid of the nerve-zapping pain that hit every time the barometer made a steep jump. My face full of post-plane crash titanium and regenerated bone acted like a weather station. I couldn’t find doctors with experience in my kind of injury. “Folks with injuries like yours are usually dead . . .” My husband turned to the military world, with the recent flood of soldiers with faces and other body parts that need rebuilding. He found a team at Lackland Air Force Base in Texas reporting on repairing maxillofacial trauma...

The birds are chirping, the garden is blooming and biotech is raking in the bucks – at least in the context of the past few years.

It was another heart attack-inducing year for biotech fans, with the market gyrations approaching the speed of light.

No Abstract

The steady drip, drip, drip of excess stomach acid experienced by biotech venture capitalists, institutional investors and employees is sadly in sync with the steady drip, drip, drip of capital away from the sector.

I was dreading doing the calculations for 2011's second quarter venture rounds.

It's officially spring, and we made it past April Fool's Day still intact. News from the Middle East and the Pacific Rim is scary, but the stock market has had its best quarter in a while. So how did it work out for private biotech firms last quarter, and what might lie ahead? (BioWorld Perspectives)

The good news about fundraising in 2010: Initial public offerings (IPOs) warmed up.